Search Results

There are 21357 results for: content related to: A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome

  1. You have free access to this content
    2016 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 68, Issue S10, October 2016, Pages: 1–4550,

    Version of Record online : 8 NOV 2016, DOI: 10.1002/art.39977

  2. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Version of Record online : 5 NOV 2015, DOI: 10.1002/art.39448

  3. You have free access to this content
    ACR Meeting

    Arthritis & Rheumatism

    Volume 64, Issue S10, October 2012, Pages: S1–S1216,

    Version of Record online : 11 OCT 2012, DOI: 10.1002/art.37735

  4. Experience with low-dose rituximab in off-label indications at two tertiary hospitals

    Internal Medicine Journal

    Volume 43, Issue 8, August 2013, Pages: 871–882, J. Chay, P. Donovan, L. Cummins, P. Kubler and P. Pillans

    Version of Record online : 6 AUG 2013, DOI: 10.1111/imj.12207

  5. You have free access to this content
    Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen

    British Journal of Haematology

    Volume 154, Issue 3, August 2011, Pages: 357–362, Steven P. Treon, Christina Hanzis, Robert J. Manning, Leukothea Ioakimidis, Christopher J. Patterson, Zachary R. Hunter, Patricia Sheehy and Barry Turnbull

    Version of Record online : 25 MAY 2011, DOI: 10.1111/j.1365-2141.2011.08750.x

  6. You have free access to this content
    Rituximab for rheumatoid arthritis

    Intervention Review

    The Cochrane Library

    Maria Angeles Lopez-Olivo, Matxalen Amezaga Urruela, Lynda McGahan, Eduardo N Pollono and Maria E Suarez-Almazor

    Published Online : 20 JAN 2015, DOI: 10.1002/14651858.CD007356.pub2

  7. You have free access to this content
    Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney-Transplant Patients

    American Journal of Transplantation

    Volume 10, Issue 1, January 2010, Pages: 89–98, N. Kamar, O. Milioto, B. Puissant-Lubrano, L. Esposito, M. C. Pierre, A. Ould Mohamed, L. Lavayssière, O. Cointault, D. Ribes, I. Cardeau, M. B. Nogier, D. Durand, M. Abbal, A. Blancher and L. Rostaing

    Version of Record online : 28 JUL 2009, DOI: 10.1111/j.1600-6143.2009.02785.x

  8. You have free access to this content
    Poster Presentations

    Hematological Oncology

    Volume 33, Issue S1, June 2015, Pages: 181–243,

    Version of Record online : 9 JUN 2015, DOI: 10.1002/hon.2228

  9. You have free access to this content
    Rituximab in the treatment of autoimmune haemolytic anaemia

    British Journal of Clinical Pharmacology

    Volume 79, Issue 5, May 2015, Pages: 709–719, Chaturaka Rodrigo, Senaka Rajapakse and Lallindra Gooneratne

    Version of Record online : 22 APR 2015, DOI: 10.1111/bcp.12498

  10. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia

    Intervention Review

    The Cochrane Library

    Kathrin Bauer, Michaela Rancea, Verena Roloff, Thomas Elter, Michael Hallek, Andreas Engert and Nicole Skoetz

    Published Online : 14 NOV 2012, DOI: 10.1002/14651858.CD008079.pub2

  11. Rituximab (Rituxan)

    Handbook of Therapeutic Antibodies

    Stefan Dübel, Pages: 1033–1108, 2008

    Published Online : 1 FEB 2008, DOI: 10.1002/9783527619740.ch39

  12. You have free access to this content
    A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus–associated cryoglobulinemic vasculitis

    Arthritis & Rheumatism

    Volume 64, Issue 3, March 2012, Pages: 835–842, Michael C. Sneller, Zonghui Hu and Carol A. Langford

    Version of Record online : 28 FEB 2012, DOI: 10.1002/art.34322

  13. You have free access to this content
    British HIV Association guidelines for HIV-associated malignancies 2014

    HIV Medicine

    Volume 15, Issue S2, March 2014, Pages: 1–92, Writing Group, Prof Mark Bower, Dr A Palfreeman, Dr Maryam Alfa-Wali, Prof Chris Bunker, Dr Fiona Burns, Dr Duncan Churchill, Mr Simon Collins, Dr Kate Cwynarski, Dr Simon Edwards, Dr Paul Fields, Dr Kate Fife, Dr Eve Gallop-Evans, Dr Shireen Kassam, Dr Ranjababu Kulasegaram, Prof Charles Lacey, Dr Robert Marcus, Dr Sylvia Montoto, Dr Mark Nelson, Dr Tom Newsom-Davis, Dr Chloe Orkin, Ms Kate Shaw, Dr Melinda Tenant-Flowers, Dr Andrew Webb, Dr Sarah Westwell and Mr Matt Williams

    Version of Record online : 14 FEB 2014, DOI: 10.1111/hiv.12136

  14. You have full text access to this OnlineOpen article
    Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome

    British Journal of Clinical Pharmacology

    Samo Rozman, Iztok Grabnar, Srdjan Novaković, Ales Mrhar and Barbara Jezeršek Novaković

    Version of Record online : 31 MAR 2017, DOI: 10.1111/bcp.13271

  15. You have free access to this content
    Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia

    Cancer

    Volume 121, Issue 21, November 1, 2015, Pages: 3869–3876, Nicholas J. Short, Michael J. Keating, William G. Wierda, Stefan Faderl, Alessandra Ferrajoli, Zeev Estrov, Susan C. Smith and Susan M. O'Brien

    Version of Record online : 28 JUL 2015, DOI: 10.1002/cncr.29605

  16. You have free access to this content
    The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma

    British Journal of Haematology

    Volume 134, Issue 2, July 2006, Pages: 157–170, David J. Flavell, Sarah L. Warnes, Christine J. Bryson, Sarah A. Field, Armorel L. Noss, Graham Packham and Sopsamorn U. Flavell

    Version of Record online : 12 JUN 2006, DOI: 10.1111/j.1365-2141.2006.06155.x

  17. You have free access to this content
    Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action

    American Journal of Transplantation

    Volume 6, Issue 5p1, May 2006, Pages: 859–866, M. D. Pescovitz

    Version of Record online : 20 MAR 2006, DOI: 10.1111/j.1600-6143.2006.01288.x

  18. You have free access to this content
    Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

    Arthritis & Rheumatism

    Volume 64, Issue 4, April 2012, Pages: 1215–1226, Brad H. Rovin, Richard Furie, Kevin Latinis, R. John Looney, Fernando C. Fervenza, Jorge Sanchez-Guerrero, Romeo Maciuca, David Zhang, Jay P. Garg, Paul Brunetta, Gerald Appel and LUNAR Investigator Group

    Version of Record online : 27 MAR 2012, DOI: 10.1002/art.34359

  19. You have free access to this content
    Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

    British Journal of Haematology

    Volume 170, Issue 5, September 2015, Pages: 669–678, Andrew W. Roberts, Ranjana H. Advani, Brad S. Kahl, Daniel Persky, John W. Sweetenham, Dennis A. Carney, Jianning Yang, Todd B. Busman, Sari H. Enschede, Roderick A. Humerickhouse and John F. Seymour

    Version of Record online : 5 MAY 2015, DOI: 10.1111/bjh.13487

  20. You have free access to this content
    Poster Presentation Abstracts

    International Journal of Rheumatic Diseases

    Volume 19, Issue S2, September 2016, Pages: 21–293,

    Version of Record online : 19 SEP 2016, DOI: 10.1111/1756-185X.12962